Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
01
Overview
RXDX-104 is an early-stage oncology program from Ignyta that was described as a discovery effort to identify a highly selective kinase inhibitor, likely aimed at a novel, first-in-class cancer target. Public disclosures characterize RXDX-104 as part of Ignyta’s integrated Rx/Dx precision oncology strategy, but do not specify its exact molecular target, structure, indication, or clinical-stage evaluation. Available information suggests RXDX-104 remained in preclinical or discovery development and did not advance to identifiable human clinical trials or commercialization before Ignyta’s acquisition by Roche.
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on RXDX-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RXDX-104.